Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2018 financial results and business highlights.
| What: | Vericel Corporation Second-Quarter 2018 Earnings Call | |||||||||||||||||||||||||||
| When: | Monday, August 6, 2018 at 4:30pm (EDT) | |||||||||||||||||||||||||||
| Where: | ||||||||||||||||||||||||||||
| How: | The conference call will be available live in the Investors section of the Vericel website at . Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. | |||||||||||||||||||||||||||
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2018 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at until August 6, 2019. A replay of the call will also be available until 7:30pm (EDT) on August 11, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 9699288.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at .
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
VCEL-fin
Global Media Contacts:
David Schull
Russo Partners LLC
(office)
(mobile)
Karen Chase
Russo Partners LLC
(office)
(mobile)
Investor Contacts:
Chad Rubin
Solebury Trout
+1 (646) 378-2947
Lee Stern
Solebury Trout
+1 (646) 378-2922
